Brief: Spectrum Pharmaceuticals Announces FDA Acceptance Of BLA Resubmission For Eflapegrastim
11/04/2022 12:16
April 11 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF BLA
RESUBMISSION FOR EFLAPEGRASTIM
* SPECTRUM PHARMACEUTICALS INC - FDA HAS ASSIGNED SEPTEMBER
9,
2022 AS PDUFA DATE
Source text for Eikon: ID:nBw6j6f08a
Further company coverage: SPPI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary